TNSN97040A1 - Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation. - Google Patents

Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.

Info

Publication number
TNSN97040A1
TNSN97040A1 TNTNSN97040A TNSN97040A TNSN97040A1 TN SN97040 A1 TNSN97040 A1 TN SN97040A1 TN TNSN97040 A TNTNSN97040 A TN TNSN97040A TN SN97040 A TNSN97040 A TN SN97040A TN SN97040 A1 TNSN97040 A1 TN SN97040A1
Authority
TN
Tunisia
Prior art keywords
preparation
treatment
pharmaceutical compositions
osteoporosis
mixed pharmaceutical
Prior art date
Application number
TNTNSN97040A
Other languages
English (en)
Inventor
Zhu Ke Hua
D Thompson David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN97040A1 publication Critical patent/TNSN97040A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT UNE QUANTITE THERAPEUTIQUEMENT EFFICACE D'UN AGONISTE/ANTAGONISTE D'OESTROGENE ET UNE QUANTITE THERAPEUTIQUEMENT EFFICACE D'UNE PROSTAGLANDINE. ELLE CONCERNE EGALEMENT DES PROCEDES POUR LEUR PREPARATION. APPLICATION: UTILISATION DE CES COMPOSITIONS POUR LE TRAITEMENT D'AFFECTIONS DU TISSU OSSEUX, COMPRENANT L'OSTEOPOROSE.
TNTNSN97040A 1996-02-28 1997-02-26 Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation. TNSN97040A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28

Publications (1)

Publication Number Publication Date
TNSN97040A1 true TNSN97040A1 (fr) 2005-03-15

Family

ID=21754846

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97040A TNSN97040A1 (fr) 1996-02-28 1997-02-26 Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.

Country Status (45)

Country Link
US (2) US6323232B1 (fr)
EP (3) EP0883404B1 (fr)
JP (2) JPH11504352A (fr)
KR (1) KR19990087337A (fr)
CN (5) CN1515317A (fr)
AP (3) AP974A (fr)
AR (2) AR005987A1 (fr)
AT (1) ATE405273T1 (fr)
AU (1) AU703285B2 (fr)
BG (1) BG64582B1 (fr)
BR (1) BR9612533A (fr)
CA (1) CA2247420C (fr)
CL (1) CL2004000119A1 (fr)
CO (1) CO4761063A1 (fr)
CZ (1) CZ297452B6 (fr)
DE (1) DE69637651D1 (fr)
DK (1) DK0883404T3 (fr)
DZ (1) DZ2186A1 (fr)
ES (1) ES2312169T3 (fr)
GT (2) GT199700009A (fr)
HK (1) HK1018210A1 (fr)
HN (1) HN1996000101A (fr)
HR (1) HRP970118A2 (fr)
HU (1) HUP9904123A3 (fr)
ID (1) ID19886A (fr)
IL (3) IL154380A0 (fr)
IS (1) IS4812A (fr)
MA (1) MA26420A1 (fr)
NO (2) NO323648B1 (fr)
NZ (1) NZ323456A (fr)
OA (1) OA10837A (fr)
PE (2) PE58998A1 (fr)
PL (2) PL187962B1 (fr)
PT (1) PT883404E (fr)
RU (1) RU2190395C2 (fr)
SI (1) SI0883404T1 (fr)
SK (1) SK118398A3 (fr)
TN (1) TNSN97040A1 (fr)
TR (1) TR199801679T2 (fr)
TW (1) TW464496B (fr)
UA (1) UA69372C2 (fr)
UY (1) UY24472A1 (fr)
WO (1) WO1997031640A1 (fr)
YU (1) YU7797A (fr)
ZA (1) ZA971719B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
WO1998058911A2 (fr) * 1997-06-23 1998-12-30 Pfizer Inc. Agonistes de prostaglandines
EP1035853A1 (fr) * 1997-09-09 2000-09-20 The Procter & Gamble Company Procede d'augmentation du volume osseux
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (fr) 1998-02-23 2000-02-23 Pfizer Products Inc. Traitement d' anomalies du squelette
ID27027A (id) * 1998-06-03 2001-02-22 Pfizer Prod Inc 2-aminopiridin yang mengandung substituen cincin lebur
PT966968E (pt) 1998-06-16 2004-08-31 Pfizer Prod Inc Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2
ZA993975B (en) * 1998-06-16 2000-12-15 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
EP1085867A1 (fr) * 1998-06-16 2001-03-28 Pfizer Products Inc. Combinaisons therapeutiques de modulateurs (selectifs) des recepteurs des oestrogenes (serm) et de secretagogues d'hormones de croissance (ghs) pour traiter la fragilite musculo-squelettique
EP1004306A3 (fr) * 1998-08-06 2000-06-07 Pfizer Products Inc. Agonistes/antagonistes de l'estrogène
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
PL348114A1 (en) * 1998-11-03 2002-05-06 Pfizer Prod Inc Novel macrolide antibiotics
IL145124A0 (en) * 1999-03-05 2002-06-30 Procter & Gamble Methods of increasing bone volume using non-naturally-occuring fp selective agonists and antiresorptive compounds
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
IL147640A0 (en) * 2000-06-01 2002-08-14 Watson Pharmaceuticals Inc Transdermal delivery of lasofoxifene
EP1192945A3 (fr) * 2000-09-21 2004-03-03 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter l'ostéoarthrite
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
DE60108710T2 (de) * 2000-11-30 2006-05-04 Pfizer Products Inc., Groton Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel
JP2005504032A (ja) * 2001-07-31 2005-02-10 ファイザー・プロダクツ・インク エストロゲン・アゴニスト／アンタゴニスト、エストロゲン及びプロゲスチンの組み合わせを含む医薬組成物、キット及び方法
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
WO2011159769A2 (fr) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Modulateurs de récepteur d'œstrogène d'indane et utilisations de ceux-ci
AU2012315782B2 (en) 2011-09-30 2015-10-29 Perio Sciences, Llc Antioxidant compositions for treatment of inflammation or oxidative damage
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
ES2909576T3 (es) 2016-10-11 2022-05-09 Univ Duke Tratamiento con lasofoxifeno del cáncer de mama ER+
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗
WO2019204985A1 (fr) * 2018-04-24 2019-10-31 深圳华大生命科学研究院 Biomarqueur d'ostéoporose et utilisation associée
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (fr) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
EP0002097B1 (fr) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Dérivés de triphénylalcène, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
ATE66608T1 (de) 1984-04-30 1991-09-15 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0260066B1 (fr) 1986-09-11 1990-05-09 National Research Development Corporation Dérivés du tamoxifène
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
JP2557779B2 (ja) 1990-11-26 1996-11-27 アール． レッカー，ロバート ２成分型骨粗鬆症用薬剤
JPH04312526A (ja) 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5180720A (en) 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli
PL314003A1 (en) * 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
EP0739204A4 (fr) 1993-11-09 2000-03-15 Merck & Co Inc Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance
WO1995014666A1 (fr) 1993-11-24 1995-06-01 Merck & Co., Inc. Composes contenant un groupe indolyle et leur utilisation pour favoriser la liberation d'hormones(s) de croissance
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
WO1995034311A1 (fr) 1994-06-13 1995-12-21 Merck & Co., Inc. Compose de piperazine provoquant la liberation de l'hormone de croissance
EP0779813A4 (fr) * 1994-09-09 1998-05-06 Procter & Gamble Phosphonates et parathormone contre l'osteoporose
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6100301A (en) 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
HU229057B1 (en) 1996-05-07 2013-07-29 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
HUP9904049A3 (en) 1996-05-31 2000-07-28 Novo Nordisk As Growth hormone component and bone anti-resorptive agent in cyclic(coherence)treatment of osteoporosis
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
CN1515254A (zh) 2004-07-28
CA2247420C (fr) 2011-02-15
DE69637651D1 (en) 2008-10-02
HUP9904123A2 (hu) 2000-05-28
IL154379A0 (en) 2003-09-17
BG102726A (en) 1999-04-30
UY24472A1 (es) 2000-09-29
PT883404E (pt) 2008-11-14
OA10837A (en) 2001-08-13
DK0883404T3 (da) 2008-10-20
EP1236475A3 (fr) 2003-11-05
AP975A (en) 2001-06-12
US20010009920A1 (en) 2001-07-26
PL187962B1 (pl) 2004-11-30
GT199700009A (es) 1998-07-10
CZ297452B6 (cs) 2006-12-13
AP1179A (en) 2003-06-30
PL187219B1 (pl) 2004-06-30
SI0883404T1 (sl) 2008-10-31
YU7797A (sh) 2000-10-30
AR005987A1 (es) 1999-07-21
CZ271898A3 (cs) 1999-06-16
AU703285B2 (en) 1999-03-25
AP9700934A0 (en) 1997-04-30
NO323648B1 (no) 2007-06-18
MA26420A1 (fr) 2004-12-20
HRP970118A2 (en) 1998-04-30
IL154380A0 (en) 2003-09-17
CN1515316A (zh) 2004-07-28
WO1997031640A1 (fr) 1997-09-04
NO983936L (no) 1998-08-27
CO4761063A1 (es) 1999-04-27
PL328831A1 (en) 1999-02-15
NO20063853L (no) 1998-08-27
PE58998A1 (es) 1998-10-16
AU1039897A (en) 1997-09-16
TR199801679T2 (xx) 2001-06-21
IS4812A (is) 1998-07-28
EP0883404A1 (fr) 1998-12-16
NZ323456A (en) 2001-03-30
NO983936D0 (no) 1998-08-27
ATE405273T1 (de) 2008-09-15
CN1242813C (zh) 2006-02-22
AP2000001962A0 (en) 2000-12-31
ID19886A (id) 1998-08-13
CA2247420A1 (fr) 1997-09-04
CN1515317A (zh) 2004-07-28
BG64582B1 (bg) 2005-08-31
CN1209064A (zh) 1999-02-24
BR9612533A (pt) 1999-07-20
CL2004000119A1 (es) 2005-02-11
KR19990087337A (ko) 1999-12-27
EP1932543A2 (fr) 2008-06-18
ZA971719B (en) 1998-08-27
CN1515258A (zh) 2004-07-28
US6323232B1 (en) 2001-11-27
HN1996000101A (es) 1997-06-26
JP2002308771A (ja) 2002-10-23
AP2002002661A0 (en) 2002-12-31
SK118398A3 (en) 2000-07-11
EP1236475A2 (fr) 2002-09-04
IL125493A0 (en) 1999-03-12
UA69372C2 (en) 2004-09-15
ES2312169T3 (es) 2009-02-16
US7255984B2 (en) 2007-08-14
HUP9904123A3 (en) 2001-01-29
EP1932543A3 (fr) 2012-01-04
RU2190395C2 (ru) 2002-10-10
PE20011302A1 (es) 2001-12-25
AP974A (en) 2001-06-12
AR060853A2 (es) 2008-07-16
GT199700009AA (es) 1999-01-23
EP0883404B1 (fr) 2008-08-20
JPH11504352A (ja) 1999-04-20
TW464496B (en) 2001-11-21
DZ2186A1 (fr) 2002-12-02
HK1018210A1 (en) 1999-12-17

Similar Documents

Publication Publication Date Title
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
TNSN99203A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
BR9911116A (pt) Processo para tratar ou reduzir o risco de adquirir uma condição selecionada dentre o grupo consistindo de aterosclerose, câncer endometrial, câncer uterino, câncer ovariano, falta de lubrificação vaginal, e perda de massa muscular, composição farmacêutica, e, kit.
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
TNSN99079A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
DE69514813D1 (en) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
TNSN01068A1 (fr) Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
LU91281I2 (fr) Preotact-hormone parathyroïde
TNSN04191A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98104A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
BE900564A (fr) Composition pharmaceutique pour le traitement d'arteriopathies peripheriques.
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
IL127044A (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenertive diseases
TNSN99119A1 (fr) Compositions comprenant un modulateur de recepteur d'oestrogene selectif et de l'hormone parathyroidienne, et procede pour leur preparation
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
IS1801B (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga
TNSN99154A1 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de nos, leur preparation et leur utilisation